OPC1
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Cord Injury Cervical
Conditions
Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injury, Acute, Spinal Cord Injury, Spinal Cord Injury, Chronic
Trial Timeline
Jun 30, 2025 → Jun 30, 2037
NCT ID
NCT06841770About OPC1
OPC1 is a phase 1 stage product being developed by Lineage Cell Therapeutics for Spinal Cord Injury Cervical. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06841770. Target conditions include Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injury, Acute.
What happened to similar drugs?
7 of 20 similar drugs in Spinal Cord Injury Cervical were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
6
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06841770 | Phase 1 | Recruiting |
Competing Products
20 competing products in Spinal Cord Injury Cervical